作者
Tae Won Kim, Anneli Elme, Zvonko Kusic, Joon Oh Park, Anghel Adrian Udrea, Sun Young Kim, Joong Bae Ahn, Ricardo Villalobos Valencia, Srinivasan Krishnan, Ante Bilic, Nebojsa Manojlovic, Jun Dong, Xuesong Guan, Catherine Lofton-Day, A Scott Jung, Eduard Vrdoljak
发表日期
2016/11
期刊
British journal of cancer
卷号
115
期号
10
页码范围
1206-1214
出版商
Nature Publishing Group
简介
Background:
We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report the first prospective extended RAS analysis in a phase 3 trial.
Methods:
Patients with wild-type KRAS exon 2 mCRC were randomised 1: 1 to panitumumab (6 mg kg− 1 Q2W) plus BSC or BSC. On-study crossover was prohibited. RAS mutation status was determined by central laboratory testing. The primary endpoint was OS in wild-type KRAS exon 2 mCRC; OS in wild-type RAS mCRC (KRAS and NRAS exons 2, 3, and 4) was a secondary endpoint.
Results:
Three hundred seventy seven patients with wild-type KRAS exon 2 mCRC were randomised. Median OS was 10.0 months with panitumumab plus BSC vs 7.4 months with BSC (HR= 0.73; 95% CI= 0.57–0.93; P= 0.0096). RAS …
学术搜索中的文章
TW Kim, A Elme, Z Kusic, JO Park, AA Udrea, SY Kim… - British journal of cancer, 2016